New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
16:18 EDTBMRNBioMarin reports Q2 adjusted EPS 6c, consensus (42c)
Reports Q2 revenue $191.7M, consensus $158.96M. The increased non-GAAP net income for Q2 compared to the second quarter of 2013 was primarily due to strong uptake of VIMIZIM in its first full quarter of commercial sales, and significant growth in revenues from other commercial products including, Naglazyme, KUVAN, Aldurazyme and Firdapse. VIMIZIM sales topped $14M in first full quarter of sales.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
12:18 EDTBMRNPiper Jaffray biopharm analyst holds an analyst/industry conference call
Subscribe for More Information
September 17, 2014
07:43 EDTBMRNBofA/Merrill to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use